TY  - JOUR
A1  - Sebastian, Martin
A1  - Papachristofilou, Alexandros
A1  - Weiß, Christian
A1  - Früh, Martin
A1  - Cathomas, Richard
A1  - Hilbe, Wolfgang
A1  - Wehler, Thomas
A1  - Rippin, Gerd
A1  - Koch, Sven D.
A1  - Scheel, Birgit
A1  - Fotin-Mleczek, Mariola
A1  - Heidenreich, Regina
A1  - Kallen, Karl-Josef
A1  - Gnad-Vogt, Ulrike
A1  - Zippelius, Alfred
T1  - Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer
T2  - BMC cancer
N2  - Background: Advanced non-small cell lung cancer (NSCLC) represents a significant unmet medical need. Despite advances with targeted therapies in a small subset of patients, fewer than 20% of patients survive for more than two years after diagnosis. Cancer vaccines are a promising therapeutic approach that offers the potential for durable responses through the engagement of the patient's own immune system. CV9202 is a self-adjuvanting mRNA vaccine that targets six antigens commonly expressed in NSCLC (NY ESO-1, MAGEC1, MAGEC2, 5 T4, survivin, and MUC1).
Methods/Design: The trial will assess the safety and tolerability of CV9202 vaccination combined with local radiation designed to enhance immune responses and will include patients with stage IV NSCLC and a response or stable disease after first-line chemotherapy or therapy with an EGFR tyrosine kinase inhibitor. Three histological and molecular subtypes of NSCLC will be investigated (squamous and non-squamous cell with/without EGFR mutations). All patients will receive two initial vaccinations with CV9202 prior to local radiotherapy (5 GY per day for four successive days) followed by further vaccinations until disease progression. The primary endpoint of the study is the number of patients experiencing Grade >3 treatment-related adverse events. Pharmacodynamic analyses include the assessment of immune responses to the antigens encoded by CV9202 and others not included in the panel (antigen spreading) and standard efficacy assessments.
Discussion: RNActive self-adjuvanted mRNA vaccines offer the potential for simultaneously inducing immune responses to a wide panel of antigens commonly expressed in tumors. This trial will assess the feasibility of this approach in combination with local radiotherapy in NSCLC patients.
KW  - non-small cell lung cancer
KW  - CV9202
KW  - mRNA vaccine
KW  - RNActive
KW  - local radiotherapy
Y1  - 2014
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/35033
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-350330
SN  - 1471-2407
VL  - 14
IS  - 748
PB  - BioMed Central
CY  - London
ER  -